158 related articles for article (PubMed ID: 15260278)
1. Consecutive-dose pharmacokinetics of rifapentine in patients diagnosed with pulmonary tuberculosis.
Langdon G; Wilkins JJ; Smith PJ; McIlleron H
Int J Tuberc Lung Dis; 2004 Jul; 8(7):862-7. PubMed ID: 15260278
[TBL] [Abstract][Full Text] [Related]
2. Population pharmacokinetics of rifapentine and its primary desacetyl metabolite in South African tuberculosis patients.
Langdon G; Wilkins J; McFadyen L; McIlleron H; Smith P; Simonsson US
Antimicrob Agents Chemother; 2005 Nov; 49(11):4429-36. PubMed ID: 16251279
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of rifapentine in children.
Blake MJ; Abdel-Rahman SM; Jacobs RF; Lowery NK; Sterling TR; Kearns GL
Pediatr Infect Dis J; 2006 May; 25(5):405-9. PubMed ID: 16645503
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of rifapentine at 600, 900, and 1,200 mg during once-weekly tuberculosis therapy.
Weiner M; Bock N; Peloquin CA; Burman WJ; Khan A; Vernon A; Zhao Z; Weis S; Sterling TR; Hayden K; Goldberg S;
Am J Respir Crit Care Med; 2004 Jun; 169(11):1191-7. PubMed ID: 14962821
[TBL] [Abstract][Full Text] [Related]
5. The early bactericidal activities of rifampin and rifapentine in pulmonary tuberculosis.
Sirgel FA; Fourie PB; Donald PR; Padayatchi N; Rustomjee R; Levin J; Roscigno G; Norman J; McIlleron H; Mitchison DA
Am J Respir Crit Care Med; 2005 Jul; 172(1):128-35. PubMed ID: 15805182
[TBL] [Abstract][Full Text] [Related]
6. Non-linear pharmacokinetics of rifampicin in healthy Asian Indian volunteers.
Pargal A; Rani S
Int J Tuberc Lung Dis; 2001 Jan; 5(1):70-9. PubMed ID: 11263520
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of isoniazid in pulmonary tuberculosis--a comparative study at two dose levels.
Roy V; Tekur U; Chopra K
Indian Pediatr; 1996 Apr; 33(4):287-91. PubMed ID: 8772902
[TBL] [Abstract][Full Text] [Related]
8. Rifampicin reduces plasma concentrations of moxifloxacin in patients with tuberculosis.
Nijland HM; Ruslami R; Suroto AJ; Burger DM; Alisjahbana B; van Crevel R; Aarnoutse RE
Clin Infect Dis; 2007 Oct; 45(8):1001-7. PubMed ID: 17879915
[TBL] [Abstract][Full Text] [Related]
9. Rifapentine for the treatment of tuberculosis: is it all it can be?
Gordin FM
Am J Respir Crit Care Med; 2004 Jun; 169(11):1176-7. PubMed ID: 15161608
[No Abstract] [Full Text] [Related]
10. Low isoniazid concentrations and outcome of tuberculosis treatment with once-weekly isoniazid and rifapentine.
Weiner M; Burman W; Vernon A; Benator D; Peloquin CA; Khan A; Weis S; King B; Shah N; Hodge T;
Am J Respir Crit Care Med; 2003 May; 167(10):1341-7. PubMed ID: 12531776
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and tolerability of a higher rifampin dose versus the standard dose in pulmonary tuberculosis patients.
Ruslami R; Nijland HM; Alisjahbana B; Parwati I; van Crevel R; Aarnoutse RE
Antimicrob Agents Chemother; 2007 Jul; 51(7):2546-51. PubMed ID: 17452486
[TBL] [Abstract][Full Text] [Related]
12. Bioavailability of rifampicin following concomitant administration of ethambutol or isoniazid or pyrazinamide or a combination of the three drugs.
Immanuel C; Gurumurthy P; Ramachandran G; Venkatesan P; Chandrasekaran V; Prabhakar R
Indian J Med Res; 2003 Sep; 118():109-14. PubMed ID: 14700343
[TBL] [Abstract][Full Text] [Related]
13. Single and multiple dose pharmacokinetics of rifapentine in man: part II.
Keung A; Eller MG; McKenzie KA; Weir SJ
Int J Tuberc Lung Dis; 1999 May; 3(5):437-44. PubMed ID: 10331734
[TBL] [Abstract][Full Text] [Related]
14. Rifapentine pharmacokinetics in adolescents.
Marshall JD; Abdel-Rahman S; Johnson K; Kauffman RE; Kearns GL
Pediatr Infect Dis J; 1999 Oct; 18(10):882-8. PubMed ID: 10530584
[TBL] [Abstract][Full Text] [Related]
15. Daily rifapentine for treatment of pulmonary tuberculosis. A randomized, dose-ranging trial.
Dorman SE; Savic RM; Goldberg S; Stout JE; Schluger N; Muzanyi G; Johnson JL; Nahid P; Hecker EJ; Heilig CM; Bozeman L; Feng PJ; Moro RN; MacKenzie W; Dooley KE; Nuermberger EL; Vernon A; Weiner M;
Am J Respir Crit Care Med; 2015 Feb; 191(3):333-43. PubMed ID: 25489785
[TBL] [Abstract][Full Text] [Related]
16. Disposition and metabolism of 14C-rifapentine in healthy volunteers.
Reith K; Keung A; Toren PC; Cheng L; Eller MG; Weir SJ
Drug Metab Dispos; 1998 Aug; 26(8):732-8. PubMed ID: 9698286
[TBL] [Abstract][Full Text] [Related]
17. The potential use of urinary excretion data for assessing the relative bioavailability of rifampicin in fixed dose combination anti-tuberculosis formulations.
Pillai G; Ellard GA; Smith PJ; Fourie PB
Int J Tuberc Lung Dis; 2001 Aug; 5(8):691-5. PubMed ID: 11495257
[TBL] [Abstract][Full Text] [Related]
18. The pharmacokinetics of oral rifampicin in AIDS patients.
Jaruratanasirikul S
J Med Assoc Thai; 1998 Jan; 81(1):25-8. PubMed ID: 9470318
[TBL] [Abstract][Full Text] [Related]
19. Rifampicin serum levels in childhood tuberculosis.
Thee S; Detjen A; Wahn U; Magdorf K
Int J Tuberc Lung Dis; 2009 Sep; 13(9):1106-11. PubMed ID: 19723399
[TBL] [Abstract][Full Text] [Related]
20. Physiologically Based Pharmacokinetic Model of Rifapentine and 25-Desacetyl Rifapentine Disposition in Humans.
Zurlinden TJ; Eppers GJ; Reisfeld B
Antimicrob Agents Chemother; 2016 Aug; 60(8):4860-8. PubMed ID: 27270284
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
